title: Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.
abstract: Oral vitamin K antagonists are highly efficacious in the prevention and treatment of thromboembolic disease. Optimal use of these agents in clinical practice is challenged by their narrow therapeutic window. The proportion of time spent in the International Normalized Ratio (INR) range of 2.0-3.0 [time in the therapeutic range (TTR)] has been closely associated with adverse outcomes, i.e., stroke, hemorrhage, mortality. Although TTR is a validated marker, it has several limitations. TTR does not capture short-term risks associated with highly variable periods or periods characterized by extreme deviations in INR. Because TTR measurement is limited to consecutive periods of warfarin exposure, it does not inform the risks associated with gap periods of 56 days or greater as these time intervals are excluded from end-point rate calculations. Because individuals with gaps in monitoring represent a different patient population than those without gaps, e.g., less adherent, more acutely ill, more frequent transitions in health status, TTR analyses are likely most valid and informative for individuals with uninterrupted monitoring of the INR. Duration of warfarin therapy and patient-specific factors have also been shown to influence TTR. Younger age, female sex, lower income, black race, frequent hospitalizations, polypharmacy, active cancer, decompensated heart failure, substance abuse, psychiatric disorders, dementia, and chronic liver disease have all been associated with lower TTR. Targeted strategies to improve TTR are urgently needed.
authors: Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA. ehylek@bu.edu
authors: Elaine M
authors: EM
authors: Hylek
mesh_terms: D000367:Age Factors; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality; D006470:Hemorrhage / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D008107:Liver Diseases / Q000188:drug therapy / Q000401:mortality; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000401:mortality; D012737:Sex Factors; D020521:Stroke / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000401:mortality; D013923:Thromboembolism / Q000188:drug therapy* / Q000401:mortality; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K; D014859:Warfarin